Bolder BioTechnology, Inc. Protein Image
About Bolder BioTechnology

Company Profile

Bolder BioTechnology, Inc. uses advanced protein engineering and bioconjugation technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. Patients dislike injections, which leads to reduced compliance, reduced drug efficacy and, in some cases, to patients foregoing treatments with potentially beneficial drugs. There is a large unmet medical need for innovative biological drugs that do not require frequent injection. To address this need, we have developed a rich pipeline of long-acting human protein pharmaceuticals that can be administered less frequently, e.g., weekly to monthly, but with equal or superior therapeutic efficacy compared to currently marketed protein pharmaceuticals. We are a leader in the use of site-specific bioconjugation technologies to create long-acting proteins with homogeneous structures and maximum biological activities. Our scientists combine protein structure/function information with site-specific protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competitor products prepared using alternative technologies. The longer duration of action and greater potency of our products will provide patients with more convenient, safer and more effective treatments for their disease. Our diversified product pipeline includes treatments for hematological and endocrine disorders, cancer and infectious diseases. We intend to commercialize these products independently and through strategic alliances with corporate partners.



Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome

U.S. Department of Defense to Fund Research at Indiana University and Epistem UK Investigating Treatments for Radiation Sickness

Bolder BioTechnology Receives Continued NIH Support For Preclinical Development of a Long-Acting Blood Cell Growth Factor to Treat Hematopoietic Complications of Acute Radiation Exposure

Bolder BioTechnology Receives Third Year of NIH Grant to Study Use of Blood Cell Growth Factors to Treat Acute Radiation Syndrome

Bolder BioTechnology Receives Continued NIH Support to Study Effects of Long-Acting Growth Factors for Treating Acute Radiation Syndrome

Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury

Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants

View all news

About Us - Technology - Products - People - News - Careers - Contact Us

Copyright © 2009 - 2016. Bolder BioTechnology, Inc. All Rights Reserved.